证 券 研 究 报 告 可孚医疗（301087）2025 年三季报点评 推荐（维持） 核心品类表现亮眼，业务出海加速推进 目标价：56 元 事项： 公司发布 25 年三季报。25Q1-3，营业收入 23.98 亿元（+6.63%），归母净利润 2.60 亿元（+3.30%），扣非净利润 2.22 亿元（+1.46%）。25Q3，营业收入 9.02 亿元（+30.72%），归母净利润 0.93 亿元（+38.68%），扣非净利润 0.86 亿元 （+62.68%）。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 2,983 | 3,346 | 3,890 | 4,556 | | 同比增速(%) | 4.5% | 12.2% | 16.2% | 17.1% | | 归母净利润(百万) | 312 | 375 | 452 | 543 | | 同比增速(%) | 22.6% | 20.2% | 20.5% | 20.2% | | 每股 ...

在获得中介机构认可后，九安医疗的疑虑仍未完全打消。"我们对债券市场并不熟悉，真的能成功 发债吗？谁会来买？发行利率行不行？发债募来的钱能否真正用于基金出资？发债流程是不是真的高效 便捷，有没有可能半年都审不完？"为解决这些疑问，中国银行间市场交易商协会（以下简称"交易商协 会"）在天津组织的一场政策说明会起到了关键作用。 "会上，交易商协会对公司的各项疑问逐一解答，并给予了明确且肯定的答复，彻底消除了我们的 顾虑，坚定了公司发债的信心。"刘毅说，7月1日，九安医疗科技创新债券发行项目正式上报交易商协 会；8月7日，正式取得项目批文；8月21日，完成首期发行。 渤海银行既是该笔债券发行的主承销商之一，也是主要投资者。该行投资银行部总经理林杰夫对 《金融时报》记者表示，发行科技创新债券有望为九安医疗及海河海棠基金注入新动能，加速优质项目 与科创成果转化，同时撬动更多金融活水流向科技创新领域，为发掘、培养、扶持更多优质的科技创新 型企业发展壮大提供有力支持。 "本次科技创新债券新政的支持力度大，最终能够以AAA的信用评级和1.83%的发行利率，圆满完 成公司在债券市场的首次公开亮相，首期发行规模达10.5亿元。这一 ...

Group 1 - The core viewpoint of the articles highlights a positive market sentiment in the medical device sector, with the medical device ETF (562600) experiencing a slight decline of 0.34% but achieving net inflows for 17 consecutive trading days [1] - Major provinces in China, including Jiangsu, Guangdong, and Hainan, are set to launch large-scale medical equipment update projects with a total budget exceeding 4.3 billion yuan by the third quarter of 2025 [1] - The demand for home medical devices is stabilizing post-pandemic, with a gradual recovery expected in retail pharmacy non-drug segments, indicating a potential for sustained growth in the future [1] Group 2 - The long-term investment logic in the medical device sector is clear, with the medical device ETF (562600) tracking the CSI All-Share Medical Device Index, which includes 100 representative listed companies in core medical fields [2] - Investors can also consider convenient options such as the 华夏中证全指医疗器械ETF发起式联接A (021250) and 华夏中证全指医疗器械ETF发起式联接C (021251) for exposure to the medical device sector [2]

Core Viewpoint - Company has been implementing a core product focus strategy, leveraging continuous product innovation and channel development to maintain market leadership in various segments [1] Group 1: Product Performance - In the first three quarters, key products such as ventilators, hearing aids, back support devices, home testing strips, comprehensive blood and uric acid testing, and thermometers have shown strong performance, driving revenue growth [1] - These core categories have significant growth potential in both domestic and international markets [1] Group 2: Market Trends - The demand for respiratory support, hearing improvement, rehabilitation aids, and home testing is expanding due to rising health awareness, accelerated home healthcare adoption, and an aging population [1] - There is a steady increase in overseas demand for high-quality home medical devices [1] Group 3: Future Strategy - Company plans to continue strengthening technological innovation and channel expansion, enhancing its global product layout [1] - The goal is to build a competitive international brand in home health management and continuously unlock growth potential [1]

Sales Performance and Growth Expectations - The sales of self-developed ventilators have seen rapid growth since late June, becoming a key driver of revenue in Q3 [2] - Future growth is expected to continue due to increasing brand recognition and an expanding product matrix [2][3] Product Development and Innovation - The company has launched its first ventilator mask and plans to introduce multiple new masks and next-generation ventilators next year [3] - The new ventilators feature noise control comparable to imported models and include smart pressure adjustment, automatic temperature and humidity regulation, and health monitoring capabilities [3] Hearing Aid Business - The hearing aid segment has achieved steady growth, with a focus on improving the profitability of offline fitting centers [3] - A new bone conduction hearing aid, developed in collaboration with Tencent Cloud, will be officially launched at the Shanghai Import Expo [3] International Business and Strategic Collaborations - The company has successfully integrated its management team with the Ximaner business, enhancing operational efficiency and product competitiveness [4] - Overseas B2B business has shown robust growth, supported by strong customer retention and successful integration of acquisitions [4] Core Product Categories Driving Growth - Key product categories contributing to revenue growth include ventilators, hearing aids, posture correction devices, home testing kits, and blood glucose monitors [4][5] - These categories are expected to have significant growth potential in both domestic and international markets [6] AI and Smart Health Devices - The company is advancing its smart health strategy by integrating AI technology into health monitoring and respiratory support devices [7] - AI applications are expected to enhance product performance and development efficiency [7] Financial Performance and Profitability - The gross profit margin increased by 2 percentage points to 53.35% in the first three quarters of the year [8] - The company is focusing on optimizing its product structure and enhancing the value of core products to improve profitability [8] Investment in Emerging Technologies - The company has made strategic investments in brain-computer interface technologies, including a focus on bionic eye and ear products [10] - These investments aim to create synergies with existing hearing aid businesses and expand into intelligent rehabilitation solutions [10]

Key Points Summary of Kefu Medical Conference Call Company Overview - **Company**: Kefu Medical - **Industry**: Medical Devices Financial Performance - **Revenue**: For the first three quarters, revenue reached 2.398 billion yuan, a year-on-year increase of 6.63% [2][4] - **Net Profit**: Net profit was 260 million yuan, up 3.3% year-on-year [2][4] - **Operating Cash Flow**: Net cash flow from operating activities was 509 million yuan, a significant increase of 35.36% [2][4] - **Gross Margin**: Sales gross margin improved to 53.35%, an increase of 2 percentage points, indicating enhanced profitability [2][4] Business Segments Respiratory Devices - **Revenue**: Respiratory device revenue exceeded 66 million yuan in the first three quarters, with over 40 million yuan in Q3 alone [6] - **Growth Forecast**: Expected to exceed 100 million yuan for the full year, with a projected threefold growth in 2026 [6] Hearing Aids - **Revenue**: Hearing aid revenue was approximately 240 million yuan, maintaining double-digit growth [7] - **Profitability Outlook**: Expected annual revenue between 320 million to 350 million yuan, with a target of over 400 million yuan next year [7] Core Product Strategy - **Top Products**: The top ten products account for over 60% of total sales, including respiratory devices and blood glucose monitors [8] - **Sales Channels**: Online sales grew by 27%, while offline sales increased by 40%, primarily driven by partnerships with pharmacies [9] Market Expansion - **Overseas Revenue**: Overseas revenue accounted for 12.7% of total revenue, with expectations to exceed 500 million yuan by 2026 [3][9] - **Acquisition Strategy**: The company plans to acquire quality stores and expand its flagship store presence to sustain growth [5][23] Future Outlook - **Revenue Growth**: The company anticipates double-digit revenue growth for 2025, with a profit target of 356 million yuan [29][30] - **Product Development**: Focus on new product launches, including next-generation hearing aids and respiratory devices, to drive future growth [10][20] R&D and Marketing - **R&D Investment**: R&D expenses for the first three quarters were approximately 70 million yuan, with a focus on new respiratory devices and AI health management platforms [25] - **Sales Expenses**: Sales expenses reached 34%, influenced by increased spending on platforms like Douyin [25] E-commerce Strategy - **Platform Performance**: Douyin showed the highest growth rate of over 80%, while Tmall and JD.com had modest growth [5][9][26] - **Interest E-commerce**: The company is adapting to changes in interest e-commerce to maximize opportunities and drive sales [16][17] Conclusion - **Strategic Focus**: Kefu Medical is committed to enhancing its product offerings, expanding its market presence, and leveraging technology to improve operational efficiency and profitability [32][33]

Core Viewpoint - The company, Kefu Medical Technology Co., Ltd., is aiming for a dual listing on the Hong Kong Stock Exchange, leveraging its strong performance in the home medical device sector, while also facing challenges in maintaining growth and profitability [1][2]. Company Overview - Kefu Medical, known for its "Beibeijia" posture correction brand, has transformed from a small company in Changsha, Hunan, into a leading player in the home medical device market over the past 20 years [3]. - The company started with basic medical products and strategically integrated the Beibeijia brand, revitalizing it through technological upgrades and channel innovations [3][4]. Financial Performance - Kefu Medical's revenue for 2022 was approximately 2.98 billion RMB, with a slight decline to 2.85 billion RMB in 2023, followed by a recovery to 2.98 billion RMB in 2024 [9][10]. - The company reported a net profit of 302 million RMB in 2022, which decreased to 253 million RMB in 2023 but rebounded to 312 million RMB in 2024, indicating a volatile yet improving profitability trend [12][14]. Product Segmentation - The rehabilitation aids segment has shown significant growth, with revenue increasing from 526 million RMB in 2022 to 1.04 billion RMB in 2024, making it the largest revenue source for the company [10][12]. - In contrast, health monitoring and respiratory support products experienced a decline in revenue, with a drop of 16.7% and 41.35% respectively in 2024, attributed to post-pandemic normalization and increased competition [12][14]. Sales Channels - Kefu Medical has established a strong online presence, achieving 19.90 billion RMB in online sales in 2024, a year-on-year increase of 8.94%, while offline sales showed signs of recovery with 8.51 billion RMB in 2024 [18][19]. - The company is also expanding its international footprint, with overseas revenue growing over 200% in 2025, although it still represents a small portion of total revenue [19][20]. Challenges and Strategic Focus - The company faces challenges in balancing short-term gains from established products like Beibeijia with long-term investments in innovation [20]. - High sales expenses, which reached 9.73 billion RMB in 2024, are a concern, as they significantly impact net profit margins despite rising gross margins [14][15].

Key Points Summary of Kefu Medical Conference Call Company Overview - **Company**: Kefu Medical - **Industry**: Medical Devices and Healthcare Financial Performance - **H1 2025 Revenue**: 1.451 billion CNY, up 14.5% YoY [2] - **Net Profit**: 166 million CNY, down 9.5% YoY [3] - **Cash Flow**: Operating cash flow of 351 million CNY, up 14.5% YoY [3] - **Dividend**: Proposed cash dividend of 6 CNY per 10 shares, totaling 120 million CNY [3] Revenue Breakdown by Segment - **Health Monitoring**: 270 million CNY, up 12% [4] - **Medical Care**: 420 million CNY, up 9.2% [4] - **Rehabilitation Aids**: 560 million CNY, down 6.5% [4] - **Respiratory Support**: 100 million CNY, down 43.3% [4] - **Traditional Chinese Medicine Therapy**: 90 million CNY, up 6% [4] Growth Expectations - **Full Year Revenue Growth**: Expected to exceed 10% [2] - **Q3 Revenue Forecast**: Approximately 850 million CNY, up over 20% YoY [11] - **Q4 Revenue Forecast**: Expected to exceed 900 million CNY, up over 20% YoY [11] - **Segment Growth Projections**: - Rehabilitation Aids and Medical Care: ~10% growth - Health Monitoring: ~16% growth - Respiratory Support: Recovery to ~8% growth - Traditional Chinese Medicine: 10%-15% growth [12] Online and Offline Sales Channels - **Online Revenue**: 970 million CNY, 65% of total revenue [6] - **Offline Revenue**: 470 million CNY, 31% of total revenue [6] - **Sales Platforms**: Major online sales through Tmall, JD, and Douyin [6] International Expansion - **Overseas Revenue**: Approximately 100 million CNY in H1 2025, significant growth [8] - **Acquisitions**: Completed acquisitions of Shanghai Huazhou and Hong Kong Ximanla to enhance market presence in Europe and Hong Kong [8] - **Future Expectations**: Anticipated overseas revenue to exceed 300 million CNY in H2 2025 [18] Product Innovation and Development - **AI and Digitalization**: Focus on integrating AI in health monitoring devices [5][20] - **New Product Launches**: Introduction of innovative products like bone conduction hearing aids and electric wheelchairs [7] - **R&D Investment**: 40 million CNY in R&D, with a focus on improving product performance and user experience [28] Challenges and Risks - **Respiratory Support Losses**: Losses attributed to market demand fluctuations and cost control issues [16] - **Sales Expenses**: Sales expense ratio at 32%, with significant investment in hearing aid business [28] Strategic Focus - **Core Product Strategy**: Core products contribute over 80% of total revenue, with plans to develop more high-revenue products [22] - **Market Positioning**: Emphasis on enhancing brand influence and market share through product innovation and strategic acquisitions [32] Conclusion - **Overall Outlook**: Kefu Medical is positioned for growth with a focus on innovation, international expansion, and improving operational efficiency, despite facing challenges in certain segments. The company aims to leverage its strengths in AI and digital health to enhance its product offerings and market presence.

Group 1 - The stock price of Jiuan Medical is reported at 39.11 yuan, down 0.15% from the previous trading day, with a trading volume of 3.98 billion yuan [1] - Jiuan Medical primarily engages in the research, production, and sales of home medical health electronic products, including blood pressure monitors, blood glucose meters, and thermometers [1] - As of August 4, Jiuan Medical has completed a stock buyback amounting to 1.68 billion yuan this year, ranking among the top in the A-share market [1]

正式报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月26日， 鱼跃医疗 发布了2024年年报以及2025一季报。 | | | 2023 年 | | 本年比 | | | | --- | --- | --- | --- | --- | --- | --- | | | | | | 上年增 | 2022 年 | | | | 2024 年 | | | 视 | | | | | | 调整前 | 调整后 | 调整后 | 调整前 | 调整后 | | 营业收入 | 7.565.819.017.28 | 7.971.734.452.47 | 7.971.734.452.47 | -5.09% | 7.101.679.159.74 | 7.101.679.159.74 | | (元) | | | | | | | | 归属于上市 公司股东的 | 1.805.700.655.26 | 2.395.853.276.49 | 2.395.853.276.49 | -24.63% | 1.595.037.435.14 | 1.595.037.435.14 | | 净利润 | | | | | | ...